drugset / Trial / NCT00657657

Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine

NCT00657657

Phase 4 Completed 29 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelPrevention

Summary

In this study, subjects who received primary neonatal vaccination with hepatitis B vaccine at 0, 1, 2, 12 months, 20 years ago in the 103860/272 primary study will be evaluated for immunological memory to hepatitis B vaccine via assessment of the response to a vaccine challenge dose.

Timeline

Start
2008-04
Primary completion
2008-08
Completion
2008-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Engerix-B Vaccine Intramuscular